Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 18 January 2019, 13:33 HKT/SGT
Share:
    

Source: Eisai
Eisai's Notification Regarding Results of Voluntary Retirement Program

TOKYO, Jan 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the application period for the first round of the voluntary retirement program it announced on October 25, 2018, has ended and hereby discloses the results as follows:

1. Outline of Voluntary Retirement Program
a) Eligibility Criteria:
Employees 45 or older who have worked at Eisai for five consecutive years or more as of April 1, 2018
b) Effective Date of Retirement:
First round: March 31, 2019; Second round: March 31, 2020;
Third round: March 31, 2021
c) Number of Applicants Sought:
First round: Approximately 100*
d) Application Period:
First round: From December 11, 2018 to December 21, 2018 (may be subject to change based on the application situation). The application periods for the second and third rounds will cover a similar period of time each fiscal year.
e) Preferential Conditions:
A premium will be added to the normal retirement allowance. In addition, applicants will also have the option to receive job-placement assistance.

*The number of applicants sought for the second and third round will be determined in consideration of the outcome of the application situation.

2. Number of Confirmed Applicants / Total Amount of Premium Retirement Payments (First Round)
a) Number of Confirmed Applicants:
300 applicants
b) Total Amount of Premium Retirement Payments:
Approx. 6.6 billion yen

*Judging from the application situation, the application deadline was shortened from December 21, 2018 to December 19, 2018.

3. Impact on Financial Performance
The sum total of premium retirement payments associated with the implementation of the first round of this program will be recorded as expenses in the settlement of accounts for the third quarter of the fiscal year ending March 31, 2019. The full-year consolidated financial results forecasts for the fiscal year ending March 31, 2019 previously announced on November 1, 2018 includes a certain level for these expenses, and based on recent trends in business performance and other factors, there is no change to the full-year consolidated financial results forecasts.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 12, 2025 12:20 HKT/SGT
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 8, 2025 16:49 HKT/SGT
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
Sept 4, 2025 09:56 HKT/SGT
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
Sept 3, 2025 10:32 HKT/SGT
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sept 1, 2025 12:44 HKT/SGT
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Aug 29, 2025 17:17 HKT/SGT
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 25, 2025 18:30 HKT/SGT
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
Aug 18, 2025 08:11 HKT/SGT
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: